Nicole D Fleming1, Shannon N Westin2, J Alejandro Rauh-Hain2, Pamela T Soliman2, Bryan M Fellman3, Robert L Coleman4, Larissa A Meyer2, Aaron Shafer2, Lauren P Cobb2, Amir Jazaeri2, Karen H Lu2, Anil K Sood2. 1. Department of Gynecologic Oncology and Reproductive Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States of America. Electronic address: nfleming@mdanderson.org. 2. Department of Gynecologic Oncology and Reproductive Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States of America. 3. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States of America. 4. US Oncology Research, The Woodlands, TX. 77380, United States of America.
Abstract
OBJECTIVES: To evaluate the factors associated with response to neoadjuvant chemotherapy (NACT) and the ability to undergo interval tumor reductive surgery (iTRS) in patients with advanced ovarian cancer. METHODS: We performed a retrospective review from April 2013 to March 2019 of patients with advanced stage ovarian cancer triaged to NACT based on our standard triage algorithm. Clinicopathologic and treatment data were analyzed for factors associated with response to NACT, outcomes at iTRS, and their impact on progression-free survival (PFS). RESULTS: 562 patients met inclusion criteria and triaged to NACT following laparoscopy (n = 132) or without laparoscopy (n = 430). 413 patients underwent iTRS (74%). Factors that correlated with a patient reaching iTRS included increasing age (p < 0.001), higher Charlson comorbidity index (p < 0.001), ECOG status 2 or 3 (<0.001), and laparoscopic assessment (<0.001). Patients with CA-125 ≤ 35 U/mL at iTRS had higher rates of complete gross resection (88% vs. 65%, p < 0.001) and improved PFS (16.8 vs. 12.7 months, p < 0.001). Patients receiving dose-dense paclitaxel (76% vs. 60%, p = 0.004) and CA-125 ≤ 35 U/mL at iTRS (85% vs. 66%, p < 0.001) had higher rates of complete radiographic response. On multivariate analysis, germline BRCA 1/2 mutation (p = 0.001), iTRS vs. no surgery (R0, p < 0.001; ≤1 cm, p < 0.001; >1 cm, p < 0.001), dose-dense chemotherapy (p = 0.01), and CA-125 ≤ 35 U/mL at iTRS (p = 0.001) were independent significant factors affecting PFS. CONCLUSIONS: Normalization of CA-125 at the time of iTRS following NACT may serve as a surrogate marker for prognosis in this high-risk population. Our NACT cohort experienced improved response rates and PFS with dose-dense therapy compared to conventional dosing.
OBJECTIVES: To evaluate the factors associated with response to neoadjuvant chemotherapy (NACT) and the ability to undergo interval tumor reductive surgery (iTRS) in patients with advanced ovarian cancer. METHODS: We performed a retrospective review from April 2013 to March 2019 of patients with advanced stage ovarian cancer triaged to NACT based on our standard triage algorithm. Clinicopathologic and treatment data were analyzed for factors associated with response to NACT, outcomes at iTRS, and their impact on progression-free survival (PFS). RESULTS: 562 patients met inclusion criteria and triaged to NACT following laparoscopy (n = 132) or without laparoscopy (n = 430). 413 patients underwent iTRS (74%). Factors that correlated with a patient reaching iTRS included increasing age (p < 0.001), higher Charlson comorbidity index (p < 0.001), ECOG status 2 or 3 (<0.001), and laparoscopic assessment (<0.001). Patients with CA-125 ≤ 35 U/mL at iTRS had higher rates of complete gross resection (88% vs. 65%, p < 0.001) and improved PFS (16.8 vs. 12.7 months, p < 0.001). Patients receiving dose-dense paclitaxel (76% vs. 60%, p = 0.004) and CA-125 ≤ 35 U/mL at iTRS (85% vs. 66%, p < 0.001) had higher rates of complete radiographic response. On multivariate analysis, germline BRCA 1/2 mutation (p = 0.001), iTRS vs. no surgery (R0, p < 0.001; ≤1 cm, p < 0.001; >1 cm, p < 0.001), dose-dense chemotherapy (p = 0.01), and CA-125 ≤ 35 U/mL at iTRS (p = 0.001) were independent significant factors affecting PFS. CONCLUSIONS: Normalization of CA-125 at the time of iTRS following NACT may serve as a surrogate marker for prognosis in this high-risk population. Our NACT cohort experienced improved response rates and PFS with dose-dense therapy compared to conventional dosing.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Helena C Bartels; Ailin C Rogers; Veronica McSharry; Ruaidhri McVey; Thomas Walsh; Donal O'Brien; William D Boyd; Donal J Brennan Journal: Gynecol Oncol Date: 2019-07-23 Impact factor: 5.482
Authors: Alexander Melamed; Emily M Hinchcliff; Joel T Clemmer; Amy J Bregar; Shitanshu Uppal; Ian Bostock; John O Schorge; Marcela G Del Carmen; J Alejandro Rauh-Hain Journal: Gynecol Oncol Date: 2016-09-06 Impact factor: 5.482
Authors: John K Chan; Mark F Brady; Richard T Penson; Helen Huang; Michael J Birrer; Joan L Walker; Paul A DiSilvestro; Stephen C Rubin; Lainie P Martin; Susan A Davidson; Warner K Huh; David M O'Malley; Matthew P Boente; Helen Michael; Bradley J Monk Journal: N Engl J Med Date: 2016-02-25 Impact factor: 91.245
Authors: J Alejandro Rauh-Hain; Alexander Melamed; Alexi Wright; Allison Gockley; Joel T Clemmer; John O Schorge; Marcela G Del Carmen; Nancy L Keating Journal: JAMA Oncol Date: 2017-01-01 Impact factor: 31.777
Authors: Alexander Melamed; Günther Fink; Alexi A Wright; Nancy L Keating; Allison A Gockley; Marcela G Del Carmen; John O Schorge; J Alejandro Rauh-Hain Journal: BMJ Date: 2018-01-03
Authors: Sanghoon Lee; Li Zhao; Christine Rojas; Nicholas W Bateman; Hui Yao; Olivia D Lara; Joseph Celestino; Margaret B Morgan; Tri V Nguyen; Kelly A Conrads; Kelly M Rangel; Robert L Dood; Richard A Hajek; Gloria L Fawcett; Randy A Chu; Katlin Wilson; Jeremy L Loffredo; Coralie Viollet; Amir A Jazaeri; Clifton L Dalgard; Xizeng Mao; Xingzhi Song; Ming Zhou; Brian L Hood; Nirad Banskota; Matthew D Wilkerson; Jerez Te; Anthony R Soltis; Kristin Roman; Andrew Dunn; David Cordover; Agda Karina Eterovic; Jinsong Liu; Jared K Burks; Keith A Baggerly; Nicole D Fleming; Karen H Lu; Shannon N Westin; Robert L Coleman; Gordon B Mills; Yovanni Casablanca; Jianhua Zhang; Thomas P Conrads; George L Maxwell; P Andrew Futreal; Anil K Sood Journal: Cell Rep Date: 2020-04-14 Impact factor: 9.423